(live-PR.com) - BAGSVAERD, DENMARK -- (Marketwired) -- 05/17/13 -- Novo Nordisk today announced the completion of paradigm 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. ...
[Published Live-PR.com - May 17 2013]